Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 26
Hair shedding after tirzepatide
Hair shedding after tirzepatide needs assessment, not an untested swap from minoxidil to GHK-Cu or KPV.
Needle reuse and vial contamination
A used needle can carry material into another vial. CDC injection-safety guidance explains why each vial entry needs new sterile equipment.
Weight loss as disease modification
A new review asks when reducing excess adiposity changes disease outcomes, and where evidence for semaglutide and tirzepatide remains limited.
GLP-1 drugs in lipedema: survey evidence
A 2026 Obesity Pillars survey collected self-reported outcomes from people with lipedema on GLP-1 or GLP-1/GIP drugs. Patient data, but no controlled trial.
Semaglutide and NAION: reading the reply
Heberer, Bress, and Lee reply in JAMA Ophthalmology to a critique of their semaglutide-NAION research, defending active comparator design.
Semaglutide and NAION: the data debate
A 2026 JAMA Ophthalmology letter questions the evidence linking semaglutide to NAION, after the EMA listed the condition as a very rare side effect in 2025.
Semax and Selank: reports vs research
First-day users describe mild stimulation, appetite suppression, and reduced anxiety. Here is what the published research covers and where it stops.
SURMOUNT-1: glycemia markers and T2D risk
A 2026 post hoc SURMOUNT-1 analysis tested three glycemia markers in prediabetes. OGTT one-hour glucose caught 83% of T2D progressors. HbA1c alone missed 53%.
Tirzepatide and bullous pemphigoid
A case report links tirzepatide to bullous pemphigoid, an autoimmune blistering skin condition. Here is what the evidence shows and what stays unknown.
GLP-1 maintenance dosing: what trials show
Approved GLP-1 labels define a maximum dose, not a separate maintenance phase. SURMOUNT-4 and STEP-4 show what happens when you stop.
GLP-1 Drugs and Hair Loss: Cohort Evidence
A 2026 cohort study found semaglutide and tirzepatide carry higher alopecia odds than other GLP-1 drugs, with rapid weight loss as the likely driver.
Hypothalamic obesity drugs: 7 RCT review
A 2026 systematic review found just 7 RCTs on drug treatment for acquired hypothalamic obesity, with low-certainty evidence for GLP-1 receptor agonists.